Kanaph Therapeutics is a drug discovery and pre-clinical stage biotech based in Korea, with a large and small molecule two-track strategy for the development of first-in-class and best-in-class therapeutics in immuno-oncology, targeted therapy and autoimmune (ophthalmology) diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor micro-environment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.
Kanaph Therapeutics is a drug discovery and pre-clinical stage biotech based in Korea, with a large and small molecule two-track strategy for the development of first-in-class and best-in-class therapeutics in immuno-oncology, targeted therapy and autoimmune (ophthalmology) diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor micro-environment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.
Company Information
- Industry
- Company Type
- Privately Held
- Founded
- unknown
- Employee Range
- 11-50
- Revenue Range
- Not available
Location
- Address
- 5F, 3, Itaewon-ro 55ga-gil, Yongsan-gu, Seoul
- City
- Korea
- Region
- Bihar
- Postal Code
- 04348
- Country
- India